Compare Mesoblast Limited (MESO) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Palo Alto Networks Inc — how do they compare? Mesoblast Limited trades at $14.18 (market cap $1.75B), while Palo Alto Networks Inc trades at $412.62 (market cap $331.76B). The key difference: Palo Alto Networks Inc is far larger — about 189.6× Mesoblast Limited's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Palo Alto Networks Inc for 82 Days on average.
| MESO | PANW | |
|---|---|---|
Market Cap | $1.75B | $331.76B |
Volume | 239,027 | 3,886,927 |
Sector | Health | Technology |
52-Week High | $20.96 | $419.91 |
52-Week Low | $13.19 | $141.67 |
Typical Hold Time | 14 Days | 82 Days |
Enterprise Value | $1.83B | $331.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Palo Alto Networks (PANW) trades at $405.41, down 3.45% today but maintains a bullish technical outlook with strong moving average signals. The company demonstrates robust revenue growth, reaching $9.22B in 2025, though net margins compressed to 2.67%. Recent AI security initiatives, including Unit 42 AI defense service, position PANW for continued growth in the cybersecurity sector.
PANW presents a mixed investment case with strong AI-driven growth potential offset by premium valuations (P/E 1,013.93, P/S 26.99). Analyst consensus remains strongly bullish (72% buy ratings) with a $398.70 price target. Key risks include valuation sensitivity and competitive pressures in the rapidly evolving cybersecurity landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
